Table 3.
Criteria Identified to Help Select a Cohort of Individuals With End-Stage Kidney Disease Who Have No Recorded Contraindications to Kidney Transplant.
| Kidney transplant in follow-up | |||||
|---|---|---|---|---|---|
| Characteristics | Yes (N = 3215) |
No (N = 20 427) |
Entire cohort (N = 23 642) | Percentage of individuals with no transplant | Standardized difference a |
| Age >75 y | 27 (0.8) | 8879 (43.5) | 8906 (37.7) | 99.7 | 1.20 |
| End-stage kidney disease-modified Charlson Comorbidity Index score ≥7 | 12 (0.4) | 1041 (5.1) | 1053 (4.5) | 98.9 | 0.29 |
| Combination of select cancers (lung, lymphoma, cervical, colorectal, liver, multiple myeloma, and bladder cancer) b | 20-24 (0.6-0.7) | 888 (4.3) | 908-912 (3.8) | 97.3-97.7 | 0.23-0.24 |
| Home oxygen therapy c | 8 (0.2) | 1075 (5.3) | 1083 (4.6) | 99.3 | 0.31 |
| Dementia c | 9 (0.3) | 2079 (10.2) | 2088 (8.8) | 99.6 | 0.46 |
| Long-term care residenceb,c | 1-5 (0.0-0.2) | 1478 (7.2) | 1479-1483 (6.3) | 99.7-99.9 | 0.38-0.39 |
| At least one physician house call in the last year | 19 (0.6) | 1021 (5.0) | 1040 (4.4) | 98.2 | 0.27 |
Note. Data are presented as No. (%).
a
We used standardized differences to compare baseline characteristics between patients who did and did not receive a kidney transplant during follow-up. A meaningful difference is considered as a difference >0.1. Bold text represents a meaningful difference.
b
In accordance with ICES privacy policies, cell sizes less than or equal to 5 cannot be reported.
c
Lookback window >5 years from the index date (ie, looked back as far as databases available).